0000000000124669

AUTHOR

Edoardo Giovanni Giannini

showing 6 related works from this author

Primary biliary cholangitis: perception and expectation of illness

2022

Unlabelled: An important tool to explore personal experience of symptoms, treatment and clinical outcome is stratification of illness perception in patients affected by PBC. Aim: To assess the perception of illness in a cohort of Italian patients with PBC. Methods: Between June and December 2019, a specific questionnaire was administered to a pool of 210 patients from 7 tertiary Italian centers, in order to identify and assess the patient's past history, symptoms and their impact on the quality of life, follow-up, treatment and perceived satisfaction of patients toward the provided care. Results: Fatigue, pruritus, and abdominal discomfort and sicca syndrome were present in 50.4%, 45%, 30.4…

Quality of lifeMotivationHepatologyCholangitisLiver Cirrhosis BiliaryGastroenterologyIllness perceptionHumansPerceptionPBCQuestionnaire.Fatigue
researchProduct

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

2014

a b s t r a c t Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peginterferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase. Sust…

RegistrieMaleCirrhosismedicine.disease_causePolyethylene GlycolGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis VirusesHepatitis ViruseProspective StudiesViralRegistriesChronicProspective cohort studyDrug CarrierDrug CarriersSettore MED/12 - GastroenterologiaMedicine (all)GastroenterologyRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeItalyCombinationRNA ViralPopulation studyDrug Therapy CombinationFemaleHumanmedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonRibavirin; Sustained virological response (SVR); TreatmentAntiviral AgentsFollow-Up StudieRibavirin; Sustained virological response (SVR); Treatment; Hepatology; GastroenterologyDrug TherapyInternal medicineRibavirinmedicineHumansAntiviral AgentHepatologybusiness.industryRibavirinInterferon-alphaHCV therapyHepatitis C ChronicHepatologymedicine.diseaseClinical trialTreatmentProspective StudiechemistryImmunologyRNARibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; RegistriesbusinessRibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; Registries; Gastroenterology; Hepatology; Medicine (all)Follow-Up StudiesSustained virological response (SVR)
researchProduct

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver …

2015

In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (…

MaleSettore MED/09 - Medicina Internaboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Infectious Diseases; Virology; Medicine (all)Hepacivirusboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Virology; Infectious DiseasesGastroenterologyIFN-based therapy; boceprevir; cirrhosis; first-generation protease inhibitors; hepatitis Cfirst-generation protease inhibitorchemistry.chemical_compoundLiver diseaseboceprevirMedicineViralChronicSettore MED/12 - Gastroenterologiaboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy; Combination; Female; Hepacivirus; Hepatitis C; Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA; Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Infectious Diseases; Virology; Medicine (all)Medicine (all)virus diseasesHepatitis CMiddle AgedViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CInfectious DiseasesTreatment OutcomeItalyHCVCombinationRNA ViralDrug Therapy CombinationFemaleViral loadHumanAdultmedicine.medical_specialtyProlineAlpha interferonInfectious DiseaseAntiviral AgentsDrug TherapyVirologyInternal medicineBoceprevirRibavirinboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis c; IFN-based therapy; adult; aged; antiviral agents; drug therapy combination; female; hepacivirus; hepatitis c chronic; humans; interferon-alpha; italy; male; middle aged; proline; RNA viral; ribavirin; spain; treatment outcome; viral load; hepatology; infectious diseases; virologyHumansDecompensationAdverse effectAgedAntiviral AgentIFN-based therapyHepaciviruHepatologybusiness.industryRibavirincirrhosisInterferon-alphaHepatitis C Chronicmedicine.diseasedigestive system diseasesboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Loadfirst-generation protease inhibitorschemistrySpainImmunologyRNAbusinesscirrhosi
researchProduct

Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

2008

BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis trea…

Liver CirrhosisMalePathologyCirrhosisAdult Antibodies; Viral; blood Carcinoma; Hepatocellular; blood/pathology/virology Cohort Studies Female Hepatitis B Core Antigens; immunology Hepatitis B virus; immunology Hepatitis C; blood/complications/pathology Humans Liver Cirrhosis; blood/etiology/pathology Liver Neoplasms; blood/pathology/virology Male Middle Aged Retrospective Studies Risk FactorsAntibodies ViralGastroenterologyanti HBcCohort StudiesimmunologyRisk FactorsHBVViralHCCCIRRHOSISLiver NeoplasmsGastroenterologyvirus diseasesHBV HCV COINFECTIONMiddle AgedHepatitis B Core AntigensHepatitis CAdult; Antibodies Viral; Carcinoma Hepatocellular; Cohort Studies; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; GastroenterologyHepatocellular carcinomaHCVFemaleAdultmedicine.medical_specialtyHepatitis B virusCarcinoma Hepatocellularblood/pathology/virologyAntibodiesbloodblood/complications/pathologyInternal medicinemedicineHumansIn patientHEPATOCELLULAR CARCINOMAHEPATOCELLULAR CARCINOMA; HCV; HBV; CIRRHOSIS; HBV HCV COINFECTIONRetrospective StudiesHepatologybusiness.industryCarcinomaCancerHepatocellularmedicine.diseasedigestive system diseasesblood/etiology/pathologybusiness
researchProduct

Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis

2018

Although studies suggest decreased incident hepatocellular carcinoma (HCC) after treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, data are conflicting regarding risk and aggressiveness of recurrence in patients who have a history of treated HCC. This review analyses data available in literature in order to elucidate the impact of DAAs on the risk of HCC recurrence after successful treatment of the tumor. Overall 24 papers were identified. The available data cannot be considered definitive, but the initial alarmist data indicating an increased risk of recurrence have not been confirmed by most subsequent studies. The suggested aggressive pattern (rapid gr…

OncologyLiver CirrhosisCirrhosisSustained Virologic ResponseDAA; HCC; HCV; Recurrencemedicine.disease_causelaw.invention0302 clinical medicineRandomized controlled triallawDAA; HCC; HCV; Recurrence; Antiviral Agents; Carcinoma Hepatocellular; Disease Progression; Hepatitis C Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence Local; Neoplasm Staging; Risk Assessment; Sustained Virologic ResponseRecurrenceHCCChronicLiver NeoplasmsGastroenterologyhepatocellular carcinomaHepatitis CLocalDAA; HCC; HCV; Recurrence; Hepatology; Gastroenterology030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease Progression030211 gastroenterology & hepatologyRisk assessmentDirect actingRisk analysismedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusAntiviral AgentsRisk AssessmentDAA HCC HCV Recurrence03 medical and health sciencesInternal medicinemedicineHumansAntiviral treatmentDAANeoplasm StagingHepatologybusiness.industryCarcinomaHepatocellularHepatitis C Chronicmedicine.diseaseSettore MED/18 - Chirurgia GeneraleNeoplasm RecurrenceNeoplasm Recurrence Localbusiness
researchProduct

A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study

2021

Simple Summary Accurate prognostic systems capable of predicting the survival of patients with advanced hepatocellular carcinoma undergoing Sorafenib therapy are still lacking. The search for the ideal predictive tool for survival and drug response is justified by the recent availability of several other drugs effective for these patients, licensed as first- and second-line treatment, other than reducing adverse events and costs. In this study, we aimed to identify simple demographic and clinical parameters able to predict survival and Sorafenib response in a large multicenter cohort. In this study, we showed that patient’s general status, liver function and damage laboratory parameters and…

Cohort study; Hepatocellular carcinoma; Prognosis; Sorafenib; SurvivalSorafenibOncologyCancer Researchmedicine.medical_specialtyPrognosisurvivalArticle03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicinecohort studyRC254-282Settore MED/12 - GastroenterologiaPerformance statusProportional hazards modelbusiness.industryHazard ratioNeoplasms. Tumors. Oncology. Including cancer and carcinogenshepatocellular carcinomaNomogrammedicine.diseaseOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologysorafenibprognosisLiver cancerbusinessmedicine.drugCancers
researchProduct